10-K: Lakeside Holdings: Revenue Dip, Pharma Expansion

Lakeside Holding Limited reported a significant net loss and revenue decline in its core logistics business for fiscal year 2025, partially offset by a new pharmaceutical distribution segment.

Summary

• Total revenue decreased by 2.9% to $17.8 million in fiscal year 2025 from $18.3 million in fiscal year 2024.
• Revenue from cross-border freight solutions, the core business, decreased by 17.9% to $15.0 million in fiscal year 2025.
• A new pharmaceutical distribution segment, launched in December 2024, generated $2.8 million in revenue in fiscal year 2025.
• Gross profit decreased by 22.5% to $2.9 million in fiscal year 2025 from $3.7 million in fiscal year 2024.
• Net loss significantly widened to $5.2 million in fiscal year 2025 from $0.2 million in fiscal year 2024.
• Operating expenses increased by 84.8% to $7.8 million in fiscal year 2025, primarily due to higher selling, general, and administrative costs.
• Cash balance as of June 30, 2025, was $5.0 million, with positive working capital of $0.6 million.
• An Initial Public Offering (IPO) was completed on July 1, 2024, raising approximately $5.35 million in net proceeds.
• The company acquired 100% equity interest in Hupan Pharmaceutical in late 2024 for $0.3 million.
• Material weaknesses in internal control over financial reporting were identified, including inadequate segregation of duties and insufficient written policies for U.S. GAAP and SEC reporting.

Sentiment

Score: 3

Explanation: The company experienced a significant decline in its core logistics revenue and a substantial increase in net loss, coupled with identified material weaknesses in internal controls. While the new pharmaceutical segment shows promise, the overall financial performance and operational challenges present a negative outlook.

Positives

• Successfully launched a new pharmaceutical distribution business segment in China, generating $2.8 million in revenue with a high gross margin of 56.1% in its first year.
• Completed an Initial Public Offering (IPO) on July 1, 2024, raising approximately $5.35 million in net proceeds, and subsequently raised additional capital through private placements and convertible debts.
• Maintained positive working capital of $0.6 million and a current ratio of 1.06:1 as of June 30, 2025.
• Established an extensive collaboration network of over 200 domestic ground transportation carriers and major global ocean/air carriers.
• Developed a scalable proprietary technology platform (American Bear Logistics Data Tool Management Platform) and an intelligent warehousing system to enhance operational efficiency.
• Reported no material cybersecurity incidents as of the filing date.

Negatives

• Total revenue decreased by 2.9% from $18.3 million in fiscal year 2024 to $17.8 million in fiscal year 2025.
• Revenue from cross-border freight solutions decreased significantly by 17.9% due to U.S. policy changes (termination of $800 de minimis rule, new tariffs) and an overall economic downturn.
• Net loss widened substantially to $5.2 million in fiscal year 2025 from $0.2 million in fiscal year 2024, representing a 2,198.1% increase.
• Gross profit decreased by 22.5% to $2.9 million, with the gross margin for cross-border freight solutions declining from 20.3% to 8.8%.
• Operating expenses surged by 84.8% to $7.8 million, driven by higher selling, general, and administrative expenses.
• General and administrative expenses increased by 79.1% to $7.4 million, partly due to costs associated with operating as a listed company and the launch of the new pharmaceutical distribution segment.
• Interest expenses increased by 271.5% to $0.4 million, mainly due to late credit card payments and interest expense in connection with convertible notes.
• Identified material weaknesses in internal control over financial reporting, specifically lacking adequate segregation of duties and sufficient written policies for U.S. GAAP and SEC reporting.

Risks

• Changes in the competitive environment or damage to reputation.
• Fluctuations in currency exchange, interest, or inflation rates.
• Changes in accounting estimates and assumptions.
• Challenges in complying with differing or conflicting laws and regulations across jurisdictions.
• Failure to protect intellectual property rights or allegations of infringement.
• Failure to retain, attract, and develop experienced and qualified personnel.
• Effects of natural or man-made disasters, including health pandemics and climate change.
• System or network disruption or breach resulting in operational interruption or improper disclosure of confidential data.
• Ability to develop, implement, update, and enhance new technology.
• Actions taken by third parties that perform aspects of business operations and client services.
• Costs and risks associated with growing and developing the business and entering new lines of business or products.
• Heightened regulatory and compliance requirements for handling and distributing medical products in the new pharmaceutical segment.
• Increased working capital exposure from holding inventory in the pharmaceutical segment.
• Greater operational complexity in maintaining product quality and safety in the pharmaceutical segment.
• Inability to effectively control costs (transportation, labor, fuel prices, leasing costs) and adjust fee rates.
• Impact of U.S. tariff policies and regulations, including the termination of the $800 de minimis threshold and new tariffs on small packages, which have already reduced shipment volume.
• Uncertainty regarding future U.S.-China trade regulations and their potential to create further disruptions and uncertainties.
• Potential for significant payments, accruals, or material deviation from tax positions due to ongoing tax examinations.
• Concentration of credit risk with cash deposits exceeding FDIC/FSD insured limits in some banks.
• Liquidity risk arising from financial obligations exceeding available financial assets.
• Dependence on a few significant customers and suppliers (one third-party customer generated over 10% of total revenue in FY2025; three third-party customers generated over 10% of accounts receivable as of June 30, 2025; one third-party supplier represented over 10% of cost of revenue in FY2025; one third-party supplier represented over 10% of accounts payable as of June 30, 2025).

Future Outlook

Management anticipates significant uncertainty regarding future tariff policies, trade regulations between the U.S. and China, and the regulatory environment affecting e-commerce platforms in the U.S. These factors are expected to continue influencing cross-border freight activity in the near term, potentially reducing import volumes due to increased costs. The company remains committed to exploring new customer opportunities and maintaining strong relationships with existing clients, while also planning to sublease one of its warehouses in Chicago in the next fiscal year to mitigate costs.

Management Comments

• We will continue to actively monitor the situation and may take further actions that alter our business operations as may be required by federal, state, local or foreign authorities, or that we determine are in the best interests of our employees, customers, service providers and stockholders.
• We will continue to actively monitor the situation and consider strategic adaptation to maintain service levels and profitability.
• We plan to sublease one of the warehouses in Chicago in the next fiscal year.
• We remain committed to exploring new customer opportunities while maintaining strong relationships with our existing clients.

Industry Context

The company operates in a highly fragmented and fiercely competitive market for integrated cross-border supply chain solutions, with a strategic focus on the Asian market. The industry is evolving, with customers increasingly seeking reliable service providers that have invested in innovation to de-risk their supply chains. The company's performance is significantly impacted by macroeconomic conditions, U.S.-China trade tensions, and regulatory changes, such as the termination of the $800 de minimis rule and new tariffs, which have disrupted cross-border commerce. The expansion into pharmaceutical distribution represents a diversification strategy into a highly regulated sector, potentially aligning with broader trends of specialized logistics services.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• Not a party to, nor aware of, any legal proceedings, investigations or claims which are likely to have a material adverse effect on business, financial condition or results of operations.

Related Party Transactions

• Revenue from Weship: $8,241 (FY2025), $28,870 (FY2024), $109,314 (FY2023).
• Revenue from ABL Wuhan: $1,196,119 (FY2025), $1,835,377 (FY2024).
• Revenue from ABL Shenzhen: $698,371 (FY2025).
• Revenue from ABL LAX: $3,084 (FY2025).
• Cost of revenue charged by Weship: $869,975 (FY2025), $1,555,680 (FY2024), $1,598,143 (FY2023).
• Rental income from Weship: $331,665 (FY2025), $288,185 (FY2024), $481,252 (FY2023).
• Rental income from Intermodal: $20,021 (FY2025).
• Cost of revenue charged by Intermodal: $673,823 (FY2025), $564,519 (FY2024), $325,237 (FY2023).
• Cost of revenue charged by ABL Wuhan: $133,403 (FY2025), $162,625 (FY2024).
• Cost of revenue charged by ABL LAX: $2,737 (FY2025).
• Interest expense charged by ABL Shenzhen: $2,418 (FY2025).
• Loan receivable from Weship: $148,000 (June 30, 2025).
• Loan receivable from ABL LAX: $129,741 (June 30, 2025).
• Loan payable to ABL Shenzhen: $124,176 (June 30, 2025).
• Other receivable from Weship: $753,116 (June 30, 2025).
• Other receivable from Intermodal: $99,635 (June 30, 2025).
• Other receivable from ABL LAX: $18,291 (June 30, 2025).
• Account payable to Weship: $35,003 (June 30, 2025).
• Account payable to ABL Wuhan: $9,012 (June 30, 2025).
• Account payable to Intermodal: $21,222 (June 30, 2025).
• Accounts receivable from Weship: $8,853 (June 30, 2025).
• Accounts receivable from ABL Shenzhen: $129,588 (June 30, 2025).
• Accounts receivable from ABL Wuhan: $257,890 (June 30, 2025).
• Salaries and employee benefits paid to Mr. Henry Liu: $110,205 (FY2025), $97,597 (FY2024).
• Salaries and employee benefits paid to Mr. Shuai Li: $115,282 (FY2025), $104,628 (FY2024).

Stakeholder Impact

• Shareholders: Significant net loss and revenue decline in the core business could negatively impact share price and investor confidence. Recent IPO and private placements indicate dilution risk but also capital infusion. Identified material weaknesses in internal controls pose a governance risk.
• Employees: The company had a workforce of 94 full-time employees as of June 30, 2025, with no labor unions and strong employee relations. Plans to hire additional accounting staff are in place to address internal control weaknesses.
• Customers: Core logistics customers are impacted by U.S. policy changes and economic downturn, leading to reduced shipment volumes. The new pharmaceutical distribution segment offers diversified services. Maintaining high service quality is critical for customer retention.
• Suppliers: The company relies on an extensive network of global freight carriers and domestic ground transportation carriers. Changes in the financial stability or capacity of these carriers, or governmental regulations, could adversely affect business operations.
• Creditors: Increased interest expenses and the issuance of convertible debts indicate higher leverage. Loan repayments are ongoing, and the company's ability to generate sufficient cash flow from operations is crucial for meeting obligations.

Next Steps

• Expand customer base and improve service quality in cross-border logistics.
• Effectively manage risks and maintain high service standards and compliance in the new pharmaceutical distribution segment.
• Implement additional cost control measures, including potentially subleasing one of the warehouses in Chicago.
• Actively monitor U.S.-China trade policies and adapt strategic operations to mitigate adverse impacts.
• Address identified material weaknesses in internal control over financial reporting by hiring additional accounting staff, designing formal procedures, and enhancing internal audit functions.
• Fund future capital expenditures with existing cash balance, proceeds from loans, and issuance of convertible debts and private placement offerings.

Key Dates

Recommendation

The company reported a substantial net loss and a significant decline in its primary cross-border logistics revenue, driven by adverse trade policies and economic conditions. While the new pharmaceutical distribution segment shows high gross margins, it is nascent and does not yet offset the core business's struggles. The identified material weaknesses in internal controls over financial reporting raise concerns about financial reliability and governance. Despite recent capital raises, the overall financial performance and operational risks suggest a challenging outlook, making the stock a 'sell' for a seasoned investor.

Keywords

Cross-border logistics, Supply chain solutions, Pharmaceutical distribution, Freight forwarding, SEC 10-K, Financial results, Trade tariffs, E-commerce logistics, China market, U.S. market, Nasdaq, Risk management, Internal controls, Working capital, Net loss, Revenue decline, Acquisition